Cenobamate beyond Epilepsy: exploring associations with vascular risk factors through serological markers
Epilepsy & Behavior · 2026
DOI: 10.1016/j.yebeh.2026.110890 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsy & Behavior, 2026. Verfasst von Anthony D Jimenez und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Comprehensive Epilepsy Center, Yale University School of Medicine, New Haven, CT, USA. Hauptthemen laut MEDLINE: Anticonvulsants, Tetrazoles, Epilepsy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Swebilius Foundation.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVES: Anti-seizure medications (ASM) variably affect cardiovascular and cerebrovascular risk factors, as evidenced by changes in associated serological biomarkers. While enzyme-inducing ASM vascular effects are well studied, those of cenobamate (CNB) remain unknown. We examined CNB's impact on vascular risk by analyzing longitudinal changes in these biomarkers, addressing an important knowledge gap as CNB use expands in epilepsy management. METHODS: We conducted a retrospective analysis of adults (≥18 years) receiving CNB with ≥ 3 serial biomarker measurements (either 2 pre-/1 post-CNB or 1 pre-/2 post-CNB). Analyzed biomarkers comprised glycosylated hemoglobin (HbA1c), international normalized ratio (INR), and the lipid profile consisting of low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), triglycerides (TG), and total cholesterol (TC). RESULTS: Among 413 patients receiving CNB, 96 patients met inclusion criteria (56 HbA1c, 50 lipid profile analysis, 21 INR). HbA1c increased significantly by 0.24 % post-CNB (p = 0.017), with greater increases in patients with diabetes mellitus (DM) (0.48 % vs. 0.09 % in non-diabetics, p < 0.001). Insulin use was associated with a further HbA1c rise (0.61 %increase, p=
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Comprehensive Epilepsy Center, Yale University School of Medicine, New Haven, CT, USA.
- Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA.
- Department of Neurology, Comprehensive Epilepsy Center, Yale University School of Medicine, New Haven, CT, USA; Sorbonne Université, Institut du Cerveau, Paris Brain Institute, ICM, AP-HP, Hôpital de la Pitié-Salpêtrièr…
- Northwestern University, Evanston, IL, USA.
- Department of Neurology, Comprehensive Epilepsy Center, Yale University School of Medicine, New Haven, CT, USA; Department of Internal Medicine, Medical University of South Carolina, SC, USA.
- Yale New Haven Hospital, New Haven, CT, USA.
Förderung
- Swebilius Foundation
Zitieren
APA
Jimenez, A. D., Zhou, X., Agadzhanian, N., Hanin, A., Toghramadjian, I., Okafor, C. M., Nuthalapati, P., Tallapalli, J., Sakya, S., Singh, A., Altalib, H. H., Mattson, R., Schoenfeld, M. H., & Herlopian, A. (2026). Cenobamate beyond Epilepsy: exploring associations with vascular risk factors through serological markers. Epilepsy & Behavior. https://doi.org/10.1016/j.yebeh.2026.110890
Vancouver
Jimenez AD, Zhou X, Agadzhanian N, Hanin A, Toghramadjian I, Okafor CM, et al. Cenobamate beyond Epilepsy: exploring associations with vascular risk factors through serological markers. Epilepsy & Behavior. 2026. doi:10.1016/j.yebeh.2026.110890
BibTeX
@article{Jimenez2026,
author = {Jimenez, Anthony D and Zhou, Xin and Agadzhanian, Nikol and Hanin, Aurelie and Toghramadjian, Isabel and Okafor, Chinenye M and Nuthalapati, Poojith and Tallapalli, Jayanth and Sakya, Sagune and Singh, Anuradha and Altalib, Hamada H and Mattson, Richard and Schoenfeld, Mark Howard and Herlopian, Aline},
title = {Cenobamate beyond Epilepsy: exploring associations with vascular risk factors through serological markers},
journal = {Epilepsy & Behavior},
year = {2026},
doi = {10.1016/j.yebeh.2026.110890}
}
EUVIMED